Leishmaniasis is a parasitic disease found largely in the tropics which the World Health Organisation has estimated infects 12 million people worldwide each year. In the tropical regions Leishmaniasis is transmitted by sandflies but more recently cases have been reported in Europe among intravenous drug users with HIV. The parasite is a protozoan, a single-celled microbe, which causes symptoms ranging from skin sores to a swollen spleen or liver. If not treated, the more damaging forms of the disease can lead to death.
Many drugs against these types of parasites have toxic side effects, and can result in the death of one in ten patients. Development of safe treatments has been hampered up by the similarity between the biochemical processes of the pathogen and its human host.
However, researchers at Durham University have now developed a screening system to provide new insight into the biochemical processes at play. As a result they have identified and characterised a key enzyme which helps produce an essential cell component of protozoa called a 'complex sphingolipid', plus an inhibitor which specifically acts against this enzyme. The team have recently filed a patent for the system, which could be used in the search for non-toxic anti-protozoan drugs.
Dr Paul Denny, research leader, explains: "Identifying both the enzyme responsible for the complex sphingolipid component of protozoa plus the inhibitor which acts against this enzyme is very significant. It has marked implications in the search for anti-protozoan drugs with reduced side-effects, as knowing how to block this enzyme could prevent the production of the complex sphingolipid and thus prevent the protozoa from establishing infection.
"Potentially we can rapidly screen thousands of compounds for inhibitory effects against this enzyme. It provides a much quicker means of identifying inhibitors with the potential for drug development than is standardly used.
"Our next step is to understand the structure and mechanism of this enzyme to help inform rational drug design."
The research is supported by BBSRC. Prof Nigel Brown, BBSRC Director of Science and Technology commented: "Leishmaniasis is an extremely damaging disease which threatens 350 million people in 88 countries around the world. This research demonstrates how important fundamental bioscience research is to developing life-saving pharmaceuticals, and should provide hope to people in affected regions."
Michelle Kilfoyle | alfa
Complete skin regeneration system of fish unraveled
24.04.2018 | Tokyo Institute of Technology
Scientists generate an atlas of the human genome using stem cells
24.04.2018 | The Hebrew University of Jerusalem
At the Hannover Messe 2018, the Bundesanstalt für Materialforschung und-prüfung (BAM) will show how, in the future, astronauts could produce their own tools or spare parts in zero gravity using 3D printing. This will reduce, weight and transport costs for space missions. Visitors can experience the innovative additive manufacturing process live at the fair.
Powder-based additive manufacturing in zero gravity is the name of the project in which a component is produced by applying metallic powder layers and then...
Physicists at the Laboratory for Attosecond Physics, which is jointly run by Ludwig-Maximilians-Universität and the Max Planck Institute of Quantum Optics, have developed a high-power laser system that generates ultrashort pulses of light covering a large share of the mid-infrared spectrum. The researchers envisage a wide range of applications for the technology – in the early diagnosis of cancer, for instance.
Molecules are the building blocks of life. Like all other organisms, we are made of them. They control our biorhythm, and they can also reflect our state of...
University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.
Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.
Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.
Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...
Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.
The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...
13.04.2018 | Event News
12.04.2018 | Event News
09.04.2018 | Event News
24.04.2018 | Life Sciences
24.04.2018 | Materials Sciences
24.04.2018 | Trade Fair News